Lineage Cell Therapeutic (LCTX) Investor Presentation - Slideshow

Company Overview - Lineage Cell Therapeutics is a clinical-stage cell therapy company focused on manufacturing and transplanting various cell types to treat injuries and diseases[3] - The company possesses a world-class in-house GMP manufacturing capability and one of the largest patent portfolios in cell therapy[4, 9] - Lineage has a cost-efficient business model and is funded into 2021, assuming the payment of a $24.6 million note receivable from Juvenescence[4, 76] Clinical Programs - The company has three allogeneic ("off-the-shelf") treatments for three serious conditions: OpRegen for Dry AMD, OPC1 for Spinal Cord Injury, and VAC2 for Non-Small Cell Lung Cancer[4] - OpRegen has received $16 million in partnerships and external funding[6] - OPC1 has received over $14 million from CIRM[6, 52] - VAC2 has received over $10 million in-kind[6] OpRegen (Dry AMD) - OpRegen is a cell therapy product candidate for Dry Age-Related Macular Degeneration (AMD), which affects approximately 11 million people in the United States[13, 43] - In a Phase I/IIa clinical trial, some patients showed signs of structural improvement in the retina and decreases in drusen density[42] - Cohort 4 patients in the OpRegen Phase I/IIa trial showed improvements in Best Corrected Visual Acuity (BCVA), with some subjects gaining up to 25 letters[28, 31, 41] OPC1 (Spinal Cord Injury) - The OPC1 program has received >$14M from CIRM[6, 52] - In a Phase 1/2a study, 96% of subjects reported improved motor function[62] - The SCiStar study showed 96% durable engraftment through 1 year post-injection[67] Financial Status - As of September 30, 2019, Lineage had $35.7 million in cash, cash equivalents, and marketable securities[76] - On January 2, 2020, the company sold $5.0 million of OncoCyte (OCX) holdings[76] - The value of remaining equity holdings in OCX was $17.0 million as of January 7, 2020[76]